Seattle Genetics and Bristol-Myers report data from phase 1/2 study evaluating ADCETRIS®
Seattle Genetics and Bristol-Myers Squibb highlighted the first reported data from an ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma. December 05, 2016